Pharmaceutical composition for use in the treatment of a neurodegenerative disease

• US 9,364,519 B2
• Filed: 09/04/2012
• Issued: 06/14/2016
• Est. Priority Date: 09/01/2011
• Status: Active Grant

• Current Assignee: Sanofi-Aventis Deutschland GmbH (Sanofi ), University of Ulster
• Original Assignee: Sanofi-Aventis Deutschland GmbH (Sanofi ), University of Ulster
• Inventors: Hess, Sibylle, Hoelscher, Christian, Boehme, Andrees, Menut, Agnes, Pradier, Laurent, Taupin, Veronique
• Primary Examiner(s): Ha, Julie
• Assistant Examiner(s): Hellman, Kristina M
• Application Number:
  US13/602,913
• Publication Number:
  US 20130116179A1
• Time in Patent Office: 1,379 Days
• Field of Search: 514/11.7
• US Class Current: 1/1
• CPC Class Codes: A61K 38/2278 Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The present application relates to a pharmaceutical composition for use in the prevention or/and treatment of a neurodegenerative disease, the composition comprising desPro³⁶Exendin-4(1-39)-Lys₆-NH₂ or/and a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, adjuvant, or/and auxiliary substance. In addition, the present application relates to the use of the pharmaceutical composition for the treatment and prevention of a neurodegenerative disease.

Claims

1. A method for treating Alzheimer'"'"'s disease in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising desPro³⁶-Exendin-4(1-39)Lys₆-NH₂ or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, adjuvant, auxiliary substance, or a combination thereof.

2. The method of claim 1, wherein the progression of the Alzheimer'"'"'s disease is slowed down.

3. The method according to claim 1, wherein the Alzheimer'"'"'s disease is an early-stage Alzheimer'"'"'s disease.

4. The method of claim 1, comprising administering desPro³⁶Exendin-4(1-39)-Lys₆-NH₂ or the pharmaceutically acceptable salt thereof in a daily dose selected from the range of 10 μ

g to 20 μ

g.